MaltSci 麦伴科研

Appearance

Popular Reports / metabolism

This report is written by MaltSci based on the latest literature and research findings

How do metabolic diseases affect organ function? ​

Abstract ​

Metabolic diseases, including diabetes, obesity, and metabolic syndrome, represent significant public health challenges, affecting millions worldwide. These conditions are characterized by disruptions in normal metabolic processes, leading to a range of physiological dysfunctions that can compromise organ health. The increasing prevalence of metabolic diseases has critical implications for individual health and healthcare systems, necessitating a deeper understanding of their impact on organ function. This review provides a comprehensive overview of how metabolic diseases affect key organs such as the liver, heart, kidneys, and pancreas, focusing on the underlying mechanisms of organ damage, including inflammation, oxidative stress, and endothelial dysfunction. We discuss the epidemiology and risk factors associated with metabolic diseases, highlighting the importance of early identification and intervention. Various therapeutic approaches, including lifestyle modifications and pharmacological treatments, are examined, along with emerging therapies that target the underlying metabolic dysfunction. Finally, we identify future research directions and existing gaps in our understanding, emphasizing the need for longitudinal studies and the exploration of genetic factors that may contribute to metabolic diseases. By synthesizing current research findings, this report aims to illuminate the intricate relationship between metabolic diseases and organ health, ultimately providing insights into future research avenues and clinical implications.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Metabolic Diseases
    • 2.1 Definition and Classification
    • 2.2 Epidemiology and Risk Factors
  • 3 Impact on Organ Function
    • 3.1 Liver Dysfunction and Metabolic Disease
    • 3.2 Cardiovascular Implications
    • 3.3 Renal Complications
    • 3.4 Pancreatic Health and Diabetes
  • 4 Mechanisms of Organ Damage
    • 4.1 Inflammation and Oxidative Stress
    • 4.2 Altered Metabolic Pathways
    • 4.3 Endothelial Dysfunction
  • 5 Therapeutic Approaches
    • 5.1 Lifestyle Interventions
    • 5.2 Pharmacological Treatments
    • 5.3 Emerging Therapies
  • 6 Future Directions and Research Gaps
    • 6.1 Need for Longitudinal Studies
    • 6.2 Exploring Genetic Factors
    • 6.3 Integrating Multi-Omics Approaches
  • 7 Summary

1 Introduction ​

Metabolic diseases, including diabetes, obesity, and metabolic syndrome, have emerged as critical public health challenges, affecting millions of individuals globally. These conditions are characterized by disturbances in normal metabolic processes, which lead to a range of physiological dysfunctions. The increasing prevalence of metabolic diseases is alarming, with significant implications for individual health and healthcare systems. According to recent estimates, metabolic syndrome alone affects approximately one-quarter of adults worldwide, and it is closely linked to increased cardiovascular mortality and other serious health complications [1]. This necessitates a deeper understanding of how metabolic diseases impact organ function and overall health.

The significance of this research extends beyond individual health concerns; it encompasses broader societal implications, including economic burdens associated with healthcare costs and loss of productivity. Metabolic diseases not only compromise the quality of life for affected individuals but also contribute to rising healthcare expenditures. The need for effective therapeutic strategies to mitigate these conditions and their sequelae has never been more urgent. Thus, elucidating the mechanisms through which metabolic diseases impair organ function is essential for developing targeted interventions and improving patient outcomes.

Current research indicates that metabolic diseases can lead to organ-specific complications through various mechanisms, including inflammation, oxidative stress, and alterations in metabolic pathways [2][3]. For instance, the liver is often significantly affected, leading to conditions such as nonalcoholic fatty liver disease, while cardiovascular implications can manifest as metabolic cardiomyopathy [4][5]. Additionally, the kidneys and pancreas are also vulnerable to metabolic dysregulation, resulting in renal complications and diabetes [6][7]. The interplay between metabolic pathways and organ health is complex, underscoring the necessity for a multidisciplinary approach to address these challenges.

This review is organized into several key sections to provide a comprehensive overview of the relationship between metabolic diseases and organ function. The second section will define and classify metabolic diseases, followed by an overview of their epidemiology and associated risk factors. In the third section, we will delve into the specific impacts of metabolic diseases on organ function, focusing on the liver, heart, kidneys, and pancreas. The fourth section will explore the underlying mechanisms of organ damage, including the roles of inflammation, oxidative stress, and endothelial dysfunction. The fifth section will discuss various therapeutic approaches, encompassing lifestyle interventions, pharmacological treatments, and emerging therapies aimed at mitigating the adverse effects of metabolic diseases. Finally, the sixth section will highlight future research directions and existing gaps in our understanding, emphasizing the need for longitudinal studies and the exploration of genetic factors that may contribute to metabolic diseases.

By synthesizing current research findings, this report aims to illuminate the intricate relationship between metabolic diseases and organ health, ultimately providing insights into future research avenues and clinical implications. Understanding these connections is vital for developing effective strategies to combat the rising tide of metabolic diseases and improve the health outcomes of affected individuals.

2 Overview of Metabolic Diseases ​

2.1 Definition and Classification ​

Metabolic diseases encompass a range of disorders characterized by abnormal biochemical processes that disrupt normal metabolic function, leading to significant health complications. These diseases include conditions such as metabolic syndrome, diabetes mellitus, obesity, and nonalcoholic fatty liver disease, all of which are associated with altered organ function.

Metabolic syndrome, which affects approximately one-quarter of adults globally, is a cluster of metabolic abnormalities that primarily includes insulin resistance and central adiposity. This syndrome is closely linked to cardiovascular diseases and is a significant risk factor for all-cause mortality. The early identification of changes induced by metabolic syndrome in target organs, along with timely interventions such as weight reduction, can substantially decrease morbidity and mortality associated with these conditions[1].

The impact of metabolic diseases on organ function is multifaceted. For instance, in the context of cardiovascular health, metabolic dysfunction can lead to endothelial dysfunction, which has been recognized as a crucial factor contributing to increased cardiovascular mortality. Endothelial cells, previously thought to be inert, actively regulate vascular function through various mechanisms. Metabolic diseases can impair endothelial function, resulting in altered vascular homeostasis and increased risk of cardiovascular events[2].

Furthermore, metabolic diseases can induce chronic low-grade inflammation in metabolically significant organs, such as the liver and adipose tissue. This inflammation is often mediated by pro-inflammatory cytokines released from adipocytes and infiltrating immune cells, leading to systemic effects that compromise organ function. For example, in metabolic cardiomyopathy, which is characterized by structural and functional alterations of the heart without overt coronary artery disease, metabolic disturbances can lead to impaired myocardial relaxation and contractility due to subcellular abnormalities such as oxidative stress and mitochondrial dysfunction[3].

The liver is particularly affected by metabolic dysfunction, leading to conditions like nonalcoholic fatty liver disease (NAFLD), which can progress to steatohepatitis and cirrhosis. The interplay between cardiovascular and liver diseases has prompted calls for collaborative approaches between cardiology and hepatology to optimize patient outcomes, recognizing that systemic metabolic dysfunction affects multiple organ systems[4].

Additionally, the role of mitochondria in metabolic diseases is significant. Mitochondrial dysfunction is implicated in the pathophysiology of conditions such as type 2 diabetes and obesity, where altered mitochondrial function affects energy metabolism and contributes to the progression of cardiovascular diseases. The heart relies heavily on mitochondrial energy production, and impairments in this system can lead to severe cardiac damage[5].

In summary, metabolic diseases exert a profound influence on organ function through mechanisms involving inflammation, endothelial dysfunction, mitochondrial impairment, and systemic metabolic disturbances. The intricate relationships between these factors underscore the need for a holistic approach to the diagnosis and treatment of metabolic diseases, emphasizing the importance of addressing the underlying metabolic dysfunction to improve organ health and patient outcomes.

2.2 Epidemiology and Risk Factors ​

Metabolic diseases significantly impact organ function through various pathophysiological mechanisms. These disorders are characterized by disturbances in normal metabolic processes, leading to a range of complications that affect multiple organ systems.

One of the most critical aspects of metabolic diseases is their association with endothelial dysfunction, which has been shown to result in high cardiovascular mortality. Endothelial cells, once considered inert, are now recognized as active participants in vascular homeostasis, influencing endocrine, paracrine, and autocrine functions. The dysfunction of these cells in metabolic diseases disrupts vascular function, contributing to cardiovascular complications and highlighting the importance of endothelial health in the context of metabolic disorders (A Masha, V Martina, 2014) [2].

Metabolic dysfunction can also lead to conditions such as metabolic dysfunction-associated steatotic liver disease, where systemic metabolic alterations manifest as both cardiovascular and liver diseases. This interplay necessitates a collaborative approach between cardiology and hepatology, emphasizing the need for treatments that target the underlying metabolic dysfunction rather than merely addressing organ-specific sequelae (Paolo Raggi et al., 2024) [4].

Furthermore, metabolic syndrome, characterized by a cluster of risk factors including hyperglycemia, abdominal obesity, dyslipidemia, and hypertension, has profound effects on vascular endothelial and smooth muscle cell functions across various organs. This syndrome not only predisposes individuals to cardiovascular diseases but also affects pulmonary vascular function, increasing the risk of conditions like pulmonary hypertension (Conor Willson et al., 2019) [6].

The phenomenon of metabolic memory also plays a significant role in how metabolic diseases affect organ function. Past metabolic environments, such as prolonged hyperglycemia or hyperlipidemia, can lead to chronic inflammatory states and organ dysfunction even after the initial conditions have been resolved. This concept underscores the long-term implications of metabolic diseases on organ health and the necessity for ongoing management and intervention strategies (Hao Dong et al., 2024) [8].

In the context of organ transplantation, metabolic diseases present a significant challenge, as over 50% of solid organ transplant recipients experience metabolic complications such as posttransplant diabetes and nonalcoholic fatty liver disease. These complications can be exacerbated by immunosuppressive therapies, which highlight the critical need for tailored management strategies that consider both the metabolic status of the patient and the effects of medications used post-transplant (Mamatha Bhat et al., 2021) [7].

In summary, metabolic diseases exert multifaceted effects on organ function through mechanisms involving endothelial dysfunction, systemic metabolic alterations, and the concept of metabolic memory. These interactions necessitate a comprehensive understanding of the systemic nature of metabolic disorders and their implications for both individual organ health and overall patient management.

3 Impact on Organ Function ​

3.1 Liver Dysfunction and Metabolic Disease ​

Metabolic diseases significantly influence organ function, particularly affecting the liver, which plays a central role in various metabolic processes. Chronic liver diseases, often associated with metabolic dysfunction, can lead to a cascade of detrimental effects on liver function and overall health.

The liver is crucial for maintaining metabolic homeostasis, and its dysfunction can result from a variety of metabolic disorders. For instance, conditions such as obesity, type 2 diabetes, and metabolic syndrome are closely linked to non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). These metabolic disorders can cause hepatic steatosis, inflammation, and ultimately lead to fibrosis, cirrhosis, and hepatocellular carcinoma. Studies indicate that metabolic dysfunction-associated fatty liver disease (MAFLD) is prevalent in approximately one-third of the global population and represents a major cause of chronic liver disease today, exacerbated by the obesity epidemic [9].

Metabolic dysfunction affects liver function through several mechanisms. Insulin resistance, a hallmark of metabolic syndrome, leads to increased hepatic fat accumulation and inflammation, which are critical in the progression of liver disease [10]. Furthermore, the interplay between metabolic disorders and liver function is bidirectional; liver diseases can exacerbate metabolic dysfunction by disrupting glucose and lipid metabolism, leading to increased morbidity and mortality [11].

In the context of chronic liver disease, the liver's ability to regulate various metabolic processes is compromised. For example, hepatic stellate cell (HSC) activation is a key factor in the development of liver fibrosis and is influenced by the liver's metabolic environment. Dysregulated glucose and lipid metabolism, oxidative stress, and inflammatory responses contribute to the activation of HSCs, leading to fibrogenesis [12]. Additionally, mitochondrial dysfunction within liver cells has been implicated in the pathogenesis of steatohepatitis, with impaired fatty acid oxidation and oxidative phosphorylation being significant contributors to the disease [13].

Moreover, the relationship between liver dysfunction and cardiovascular health cannot be overlooked. Chronic liver diseases are associated with increased cardiovascular morbidity and mortality, primarily due to the systemic effects of metabolic dysfunction. For instance, patients with chronic liver failure often experience arrhythmias and cardiomyopathy, further complicating their clinical management [11].

The role of gut microbiota in influencing liver function also highlights the interconnectedness of metabolic diseases and liver health. Alterations in gut microbiota composition can exacerbate liver inflammation and contribute to the progression of liver disease, demonstrating how metabolic factors can impact hepatic outcomes through the gut-liver axis [14].

In conclusion, metabolic diseases exert profound effects on liver function through a complex interplay of mechanisms involving insulin resistance, inflammation, oxidative stress, and gut microbiota alterations. These interactions not only affect liver health but also have systemic implications, emphasizing the need for an integrated approach to managing metabolic disorders and their impact on liver function.

3.2 Cardiovascular Implications ​

Metabolic diseases significantly impact organ function, particularly with regard to cardiovascular implications. The interrelationship between metabolic disorders and cardiovascular health has garnered increasing attention in recent years, emphasizing the need to understand these complex interactions to improve patient outcomes.

Metabolic syndrome, characterized by insulin resistance, central obesity, dyslipidemia, and hypertension, is a major risk factor for cardiovascular diseases. It is associated with a heightened risk of cardiovascular mortality due to the detrimental effects on endothelial function. Endothelial dysfunction, which can arise from metabolic disturbances, compromises vascular homeostasis and contributes to the progression of atherosclerosis and other cardiovascular complications [2].

The heart itself is not merely a pump but a vital metabolic and endocrine organ that plays a crucial role in systemic metabolism. Metabolic disorders can disrupt cardiac metabolism, leading to conditions such as diabetic cardiomyopathy, where the heart's ability to utilize different energy substrates is impaired. This metabolic inflexibility can result in oxidative stress and mitochondrial dysfunction, ultimately aggravating myocardial injury [5].

Moreover, alterations in metabolic function can have systemic effects that extend beyond the heart. For instance, hepatic dysfunction can arise from metabolic diseases, leading to conditions such as non-alcoholic fatty liver disease (NAFLD), which in turn can exacerbate cardiovascular issues. A collaborative approach involving cardiology and hepatology is essential, as treatments beneficial for cardiac health may also positively affect liver function [4].

Research has shown that metabolic reprogramming within cardiomyocytes can lead to an abnormal accumulation of metabolites, which alters the cardiac microenvironment and affects the metabolism of immune cells. This interplay highlights how metabolic dysfunction can create a feedback loop that exacerbates cardiovascular diseases [15].

Furthermore, the aging process is intricately linked to metabolic changes that influence cardiovascular health. Impaired metabolic flexibility and mitochondrial dysfunction are prevalent in aged cardiomyocytes, leading to energy deficits that contribute to cardiac aging and dysfunction. Strategies such as caloric restriction, exercise, and pharmacological interventions targeting metabolic pathways show promise in mitigating age-related cardiovascular decline [16].

In summary, metabolic diseases profoundly affect organ function, particularly the cardiovascular system. The interplay between metabolic dysregulation and cardiovascular health necessitates a comprehensive understanding of the underlying mechanisms to develop effective therapeutic strategies. Addressing these interconnected issues is vital for improving outcomes in patients suffering from metabolic and cardiovascular disorders.

3.3 Renal Complications ​

Metabolic diseases significantly impact renal function, contributing to the development and progression of chronic kidney disease (CKD). The relationship between metabolic disorders, particularly obesity and metabolic syndrome, and renal complications is well-documented in the literature.

Obesity is increasingly recognized as a global health threat, leading to various metabolic and cardiovascular complications. Specifically, it is associated with the metabolic syndrome, which includes a cluster of conditions such as insulin resistance, hypertension, and dyslipidemia. Epidemiological studies have established that both obesity and the metabolic syndrome are independent risk factors for CKD, and these associations persist even when controlling for diabetes and hypertension (Guarnieri et al., 2010). The underlying mechanisms include altered levels of adipose tissue hormones, inflammation, and oxidative stress, which collectively contribute to reduced renal function. The ongoing obesity epidemic is projected to increase the prevalence of chronic uremia and features of metabolic syndrome in the coming years (Guarnieri et al., 2010).

Adipose tissue, functioning as an endocrine organ, secretes various adipokines that can have both protective and detrimental effects on renal health. For instance, adiponectin is a protective adipokine, whereas others like angiotensin II and TNFα mediate harmful effects, such as endothelial dysfunction and oxidative stress. Obesity disrupts the balance between these adipokines, exacerbating renal damage (Rüster & Wolf, 2013). Moreover, the accumulation of excessive adipose tissue around organs (peri-organ adipose tissue) has been implicated in metabolic diseases, contributing to inflammation and further complicating renal function (Zhang et al., 2023).

The metabolic syndrome also correlates with increased risks for microalbuminuria and CKD, with the risk escalating in relation to the number of syndrome components present (Locatelli et al., 2006). While hypertension and impaired glucose metabolism are significant contributors to renal impairment, obesity itself is emerging as a modifiable risk factor for CKD (Locatelli et al., 2006).

Following kidney transplantation, metabolic complications are prevalent, affecting over 50% of recipients. Common issues include weight gain, hypertension, hyperlipidemia, and insulin resistance, often exacerbated by immunosuppressive therapy. These metabolic problems can lead to adverse cardiovascular outcomes and impact both graft and patient survival (Bhat et al., 2021). Lifestyle modifications and early intervention for metabolic syndrome symptoms post-transplantation are crucial for promoting transplant function and reducing the risk of further renal complications (Phillips & Heuberger, 2012).

In summary, metabolic diseases, particularly through the mechanisms of obesity and the metabolic syndrome, exert a profound influence on renal function. This relationship underscores the necessity for integrated management strategies that address metabolic disorders to mitigate their adverse effects on kidney health and overall patient outcomes.

3.4 Pancreatic Health and Diabetes ​

Metabolic diseases, including obesity, metabolic syndrome, diabetes, and metabolic-associated fatty liver disease (MAFLD), significantly impact organ function, particularly the pancreas. The pancreas plays a crucial role in regulating metabolism through its endocrine and exocrine functions, and metabolic diseases can lead to a spectrum of pancreatic dysfunctions, including exocrine pancreatic dysfunction and new-onset diabetes.

Endocrine-disruptive chemicals (EDCs) have been linked to the exacerbation of metabolic diseases. These chemicals can induce mitochondrial dysfunction and oxidative stress, which are pivotal pathophysiological mechanisms underlying these conditions. The pancreas, being a metabolically active organ, is particularly susceptible to the adverse effects of EDCs, which impair mitochondrial function and disrupt redox homeostasis, thereby contributing to the pathogenesis of diabetes and other metabolic disorders [17].

Furthermore, the intricate relationship between the pancreas and the gut microbiota plays a significant role in metabolic health. The intestinal microbiota can influence pancreatic function through various mechanisms, including the production of bacterial metabolites such as short-chain fatty acids and modulation of immune responses. Conversely, pancreatic factors can also affect gut microbiota composition, creating a feedback loop that can exacerbate metabolic disorders [18]. This cross-talk is critical in understanding how alterations in gut microbiota can lead to pancreatic diseases and metabolic dysregulation.

In patients with metabolic disorders, the balance of metabolic hormones produced by pancreatic islet cells, such as insulin and glucagon, becomes disrupted. Insulin resistance, often seen in obesity and type 2 diabetes, leads to impaired metabolic homeostasis. The complex interplay between these hormones and their receptors is essential for maintaining glucose levels, and dysregulation can result in severe metabolic complications [19].

Moreover, pancreatitis, which can arise from metabolic disorders, has been shown to have lasting effects on pancreatic function. The condition can lead to exocrine pancreatic dysfunction and is often associated with alterations in gut microbiota, which may further complicate metabolic health. Understanding these interactions is vital for developing strategies to prevent and manage diabetes and other metabolic diseases following pancreatitis [20].

The role of the complement system in metabolic disorders also highlights the connection between innate immunity and pancreatic function. The complement system has been implicated in the metabolic dysregulation of the pancreas, adipose tissue, and liver, contributing to the development of insulin resistance and diabetes [21].

In conclusion, metabolic diseases exert profound effects on pancreatic health and function through various mechanisms, including mitochondrial dysfunction, alterations in gut microbiota, and hormonal dysregulation. A comprehensive understanding of these interactions is crucial for developing effective therapeutic strategies for managing metabolic disorders and their complications, such as diabetes.

4 Mechanisms of Organ Damage ​

4.1 Inflammation and Oxidative Stress ​

Metabolic diseases significantly impact organ function through intricate mechanisms primarily involving inflammation and oxidative stress. The relationship between these two processes is complex and self-reinforcing, leading to a cascade of cellular damage and dysfunction across various organs.

Inflammation and oxidative stress are interlinked processes that exacerbate each other, contributing to the development and progression of metabolic disorders such as type 2 diabetes, obesity, and metabolic syndrome. Inflammation can induce oxidative stress, while oxidative stress can trigger inflammatory responses, creating a vicious cycle that compromises organ function. For instance, oxidative stress leads to cellular damage, mitochondrial dysfunction, and insulin resistance, particularly affecting key metabolic organs such as adipose tissue, the liver, muscles, and the gastrointestinal tract. This results in impaired metabolic function and energy production, which is particularly detrimental in conditions like type 2 diabetes and obesity, where insulin sensitivity is critically affected [22].

Moreover, oxidative stress arises from an imbalance between oxidative and anti-oxidative mechanisms within cells, resulting in the overproduction of reactive oxygen species (ROS). Excessive ROS can damage cellular proteins, lipids, and nucleic acids, leading to significant cellular dysfunction, including loss of energy metabolism, altered cell signaling, and impaired immune responses. This cellular dysfunction is particularly evident in the context of metabolic syndrome, where chronic inflammation and oxidative stress contribute to various complications such as cardiovascular diseases and fatty liver disease [23].

The adipose tissue, in particular, plays a crucial role in metabolic health. In obesity, changes in lipid metabolism trigger immune responses within adipose tissue, leading to an increase in inflammatory cell populations and a qualitative change in their function. These immune responses can disturb metabolic organ function, resulting in systemic inflammation that further exacerbates metabolic disorders [24]. Furthermore, oxidative stress has been shown to induce pro-inflammatory cytokines and activate pathways such as NF-kB, which perpetuates inflammation and contributes to endothelial dysfunction, thus increasing the risk of cardiovascular complications [25].

Additionally, the interplay between oxidative stress and lipid metabolism is significant. Abnormal lipid metabolism can lead to the accumulation of lipid droplets in various tissues, which is often accompanied by increased oxidative stress and inflammation. This not only affects the function of the liver and adipose tissue but also contributes to systemic metabolic dysfunction [23].

In summary, metabolic diseases adversely affect organ function through mechanisms involving inflammation and oxidative stress. The resulting cellular damage and metabolic dysregulation manifest as a range of complications affecting the cardiovascular system, liver, and other vital organs. Understanding these mechanisms is crucial for developing targeted therapeutic strategies to mitigate the impact of metabolic diseases on organ function.

4.2 Altered Metabolic Pathways ​

Metabolic diseases significantly impact organ function through a variety of mechanisms, primarily by altering metabolic pathways that are crucial for maintaining cellular homeostasis and physiological balance. These alterations can lead to a cascade of detrimental effects across multiple organ systems.

Firstly, metabolic pathways are fundamental to regulating cell physiology and adapting to environmental changes. Disruptions in these pathways predispose individuals to a range of pathologies, including diabetes, obesity, and cardiovascular diseases (Chiacchiera et al., 2013) [26]. For instance, the aging cardiovascular system experiences structural and functional decline due to metabolic changes that impair mitochondrial function and energy utilization, contributing to conditions such as myocardial fibrosis and diastolic dysfunction (Gao & Finkel, 2025) [16].

In the context of cardiovascular health, metabolic syndrome—a condition characterized by hyperglycemia, abdominal obesity, dyslipidemia, and hypertension—affects vascular endothelial and smooth muscle cell functions, increasing the risk of developing cardiovascular diseases (Willson et al., 2019) [6]. The impaired metabolic flexibility in aging hearts, marked by reduced fatty acid oxidation and increased reliance on glucose, exacerbates cardiovascular aging and dysfunction (Gao & Finkel, 2025) [16].

Furthermore, chronic metabolic disturbances, such as those seen in metabolic cardiomyopathy, can lead to low-grade inflammation within metabolically active organs, including the heart. This inflammation triggers a series of subcellular abnormalities, including oxidative stress and mitochondrial dysfunction, ultimately resulting in impaired myocardial relaxation and increased cardiac fibrosis (Nishida & Otsu, 2017) [3].

Moreover, altered metabolic pathways can also influence other organ systems. For example, changes in high-density lipoprotein (HDL) metabolism have been linked to various metabolic disorders, indicating that HDL properties and functionality are crucial in the pathophysiology of conditions like obesity and nonalcoholic fatty liver disease (Constantinou et al., 2016) [27]. The connection between metabolism and organ function underscores the need for a holistic approach to treatment that considers the systemic nature of metabolic diseases.

In summary, metabolic diseases exert their detrimental effects on organ function through the disruption of metabolic pathways, leading to inflammation, oxidative stress, and impaired cellular functions. Understanding these mechanisms is vital for developing effective therapeutic strategies aimed at mitigating organ damage associated with metabolic disorders.

4.3 Endothelial Dysfunction ​

Metabolic diseases significantly impact organ function, primarily through mechanisms involving endothelial dysfunction. Endothelial cells, which line blood vessels, play a crucial role in maintaining vascular homeostasis and regulating blood flow, nutrient delivery, and waste removal. When metabolic diseases such as obesity, diabetes, and dyslipidemia occur, they can lead to endothelial dysfunction, which is a precursor to various cardiovascular and metabolic complications.

Endothelial dysfunction is characterized by a reduced bioavailability of nitric oxide (NO), increased oxidative stress, and chronic inflammation. These changes disrupt the balance between vasodilators and vasoconstrictors, leading to impaired vasodilation and increased vascular resistance. This dysfunction contributes to the development of atherosclerosis, hypertension, and other cardiovascular diseases, which are often observed in individuals with metabolic disorders [28].

Moreover, the relationship between insulin resistance and endothelial dysfunction is reciprocal. Insulin resistance, a hallmark of type 2 diabetes and obesity, is associated with impaired insulin signaling in endothelial cells. This impairment reduces the production of NO, further exacerbating endothelial dysfunction and decreasing blood flow to tissues, which negatively impacts glucose uptake and metabolic regulation [29]. The pathological mechanisms include glucotoxicity, lipotoxicity, and inflammation, all of which contribute to the development of both endothelial dysfunction and insulin resistance [30].

Additionally, endothelial cells are not merely passive barriers; they actively regulate the trans-endothelial trafficking of metabolic substrates, such as lipids and glucose, to tissues. Under conditions of metabolic stress, alterations in the trafficking of these substrates can initiate a cascade of events leading to metabolic dysfunction and cardiovascular disease [31]. The close anatomical relationship between endothelial cells and metabolically active organs suggests that any dysfunction in the endothelium can significantly impair the organ's ability to maintain metabolic homeostasis [32].

Furthermore, recent studies highlight that endothelial dysfunction is an early event in the pathogenesis of metabolic syndrome, which encompasses a cluster of conditions including hypertension, hyperglycemia, dyslipidemia, and obesity. These conditions independently contribute to vascular dysfunction, leading to increased cardiovascular morbidity and mortality [33]. The therapeutic implications are significant, as interventions that improve endothelial function have been shown to ameliorate insulin resistance and vice versa, suggesting that targeting endothelial dysfunction could be a viable strategy for managing metabolic diseases [34].

In conclusion, metabolic diseases adversely affect organ function primarily through the mechanism of endothelial dysfunction. This dysfunction not only disrupts vascular homeostasis but also contributes to the progression of cardiovascular diseases, highlighting the importance of endothelial health in the context of metabolic disorders. Understanding these mechanisms provides insights into potential therapeutic targets aimed at restoring endothelial function and improving overall metabolic health.

5 Therapeutic Approaches ​

5.1 Lifestyle Interventions ​

Metabolic diseases, including metabolic syndrome, have profound effects on organ function, primarily due to their association with systemic metabolic dysregulation. These diseases are characterized by a cluster of metabolic abnormalities such as insulin resistance, central adiposity, dyslipidemia, and hypertension, which significantly increase the risk of cardiovascular diseases and other organ-related complications. For instance, metabolic syndrome affects around a quarter of adults globally and is strongly correlated with increased cardiovascular and all-cause mortality. Early identification and intervention, such as weight reduction, can mitigate morbidity and mortality associated with these conditions[1].

The impact of metabolic dysfunction on organ systems is not limited to the cardiovascular system. It also includes alterations in liver function, as seen in metabolic dysfunction-associated steatotic liver disease, which underscores the need for a collaborative approach between cardiology and hepatology. This holistic perspective emphasizes that treatments for one organ can benefit others, suggesting a systemic approach to managing these diseases rather than isolated organ-centered care[4].

Therapeutic approaches to managing metabolic diseases primarily focus on lifestyle interventions. These interventions are critical as they can lead to significant improvements in metabolic health and organ function. For example, lifestyle modifications that include behavioral therapy, dietary changes, and increased physical activity are essential strategies for managing metabolic syndrome. Such interventions have shown promising results in maintaining long-term healthy behaviors and improving metabolic outcomes. Studies indicate that combining lifestyle modifications with pharmacotherapy can enhance treatment efficacy[35].

Physical activity plays a pivotal role in addressing metabolic disorders. It is essential not only for weight management but also for improving the function of various organ systems affected by metabolic syndrome. Regular exercise has favorable effects on all components of metabolic syndrome and reduces cardiovascular risk. Although the precise quantity and frequency of exercise required for optimal benefits remain undefined, activities such as brisk walking are encouraged as they are accessible to a wide population and have a low injury risk[36].

Dietary interventions, particularly those involving antioxidant-rich foods and polyphenols, are also vital. These dietary components can modulate inflammation and improve metabolic parameters, thus positively influencing organ health. The Mediterranean diet, which is rich in such nutrients, has been associated with protective effects against metabolic syndrome and its sequelae[37].

In summary, metabolic diseases significantly impair organ function through various mechanisms, including systemic inflammation and dysregulated metabolism. Lifestyle interventions, including dietary changes and increased physical activity, are crucial in mitigating these effects and improving overall health outcomes. The integration of these strategies can help manage metabolic disorders effectively, enhance organ function, and reduce the risk of associated complications.

5.2 Pharmacological Treatments ​

Metabolic diseases have a profound impact on organ function, contributing to a range of complications that affect multiple systems within the body. These diseases, which include obesity, diabetes, and metabolic syndrome, disrupt normal metabolic processes and lead to various pathological changes that can severely compromise organ function.

One significant area of concern is the relationship between metabolic diseases and cardiovascular health. Cardiometabolic diseases are characterized by an interplay of obesity, type 2 diabetes, and cardiovascular complications, which together present an escalating global health burden. The dysfunction of adipose tissue plays a crucial role in this context, as it is recognized as an endocrine organ whose homeostasis is vital for metabolic regulation. Adipose tissue dysfunction and inflammation can lead to cardiovascular and renal deterioration, significantly affecting heart function and increasing the risk of diseases such as heart failure and hypertension [38].

Furthermore, metabolic syndrome has been linked to alterations in vascular endothelial and smooth muscle cell functions, which can affect not only the heart but also the brain, kidneys, and peripheral vessels [6]. These changes can increase the risk of developing pulmonary vascular diseases, such as pulmonary hypertension, thereby further complicating the clinical picture of individuals with metabolic disorders [6].

The liver is another organ significantly impacted by metabolic dysfunction. Conditions like metabolic dysfunction-associated steatotic liver disease exemplify how altered metabolic functions can lead to both liver and cardiovascular diseases. This suggests a need for collaborative approaches between different medical specialties to optimize patient outcomes, as systemic metabolic dysfunction has broad implications across various organ systems [4].

Pharmacological treatments for metabolic diseases are currently limited and often ineffective, leading to poor patient compliance. However, recent advances in drug delivery strategies aim to enhance the efficacy of pharmacological interventions. Novel delivery systems, including local, targeted, and intelligent stimulus-responsive strategies, are being explored to improve treatment outcomes for metabolic disorders [39].

Moreover, there is a growing recognition of the role of mitochondrial dysfunction in metabolic diseases, particularly in relation to heart health. Mitochondria are critical for energy metabolism, and their impairment can lead to cardiac damage, a key concern in diabetic patients. Identifying therapeutic targets that can modulate mitochondrial function is an area of active research, with the potential to improve cardiac performance in the context of metabolic diseases [5].

In conclusion, metabolic diseases adversely affect organ function through complex mechanisms involving inflammation, mitochondrial dysfunction, and systemic metabolic disturbances. While current pharmacological treatments are limited, ongoing research into innovative drug delivery methods and the underlying molecular mechanisms holds promise for developing more effective therapeutic strategies.

5.3 Emerging Therapies ​

Metabolic diseases, including obesity, diabetes, and nonalcoholic fatty liver disease (NAFLD), have profound effects on organ function, primarily through mechanisms involving mitochondrial dysfunction, altered metabolic pathways, and systemic inflammation. These diseases are characterized by significant disruptions in normal metabolic processes, which can lead to various organ dysfunctions.

Mitochondria play a crucial role in energy production, calcium homeostasis, signaling, and apoptosis. Emerging evidence indicates that mitochondrial dysfunction is a key player in the pathogenesis of metabolic diseases. For instance, impaired mitochondrial function can lead to decreased oxidative capacity and bioenergetic failure in insulin-responsive tissues, exacerbating insulin resistance and contributing to the progression of metabolic disorders [40]. This dysfunction can result in various complications affecting organs such as the liver, heart, and kidneys.

The impact of metabolic diseases on organ function is not limited to mitochondrial dysfunction. The systemic effects of altered metabolic states can lead to inflammation and changes in adipose tissue function, which are linked to cardiovascular and renal deterioration [38]. The interplay between metabolic dysfunction and organ-specific complications necessitates a multidisciplinary approach to treatment, where cardiology and hepatology can collaborate to address the interconnected nature of these disorders [4].

Emerging therapeutic approaches are being explored to address these challenges. One promising strategy is mitochondrial transplantation therapy (MRT), which involves the supplementation of healthy mitochondria to restore normal mitochondrial function in affected tissues. This approach is gaining traction as a potential treatment for metabolic diseases due to its ability to directly target mitochondrial dysfunction [41].

In addition to MRT, advancements in stem cell and organoid technologies are facilitating the development of human model systems that replicate the physiological properties of human organs. These models can significantly enhance the understanding of metabolic diseases and aid in the screening of new treatments, allowing for a more personalized approach to therapy [[pmid:36071283],[pmid:38100156]].

Furthermore, pharmacological interventions targeting specific metabolic pathways in macrophages and other immune cells are also being investigated. These strategies aim to modulate the inflammatory responses associated with metabolic diseases, which could potentially alleviate organ dysfunction and improve patient outcomes [42].

Overall, the complex interplay between metabolic diseases and organ function underscores the need for innovative therapeutic strategies that not only address the metabolic abnormalities but also target the associated organ dysfunctions. As research continues to evolve, the integration of novel therapies such as MRT, stem cell technologies, and targeted pharmacological approaches holds promise for improving the management of metabolic diseases and their systemic effects on organ health.

6 Future Directions and Research Gaps ​

6.1 Need for Longitudinal Studies ​

Metabolic diseases have a profound impact on organ function, which is increasingly recognized as a complex interplay of various factors including obesity, inflammation, and alterations in metabolic pathways. Research indicates that metabolic dysfunction can lead to significant alterations in the physiological and structural integrity of multiple organs.

One critical aspect of how metabolic diseases affect organ function is through the dysfunction of peri-organ adipose tissue. The dysregulation of peri-organ adipose tissue, such as perivascular, perirenal, and epicardial fat, is closely associated with metabolic diseases and their complications. Mechanisms involved include the secretion of pro-inflammatory cytokines, activation of immunocytes, and infiltration of inflammatory cells, all of which contribute to tissue dysfunction and the progression of metabolic diseases [43]. This suggests that the inflammatory environment created by excess adipose tissue can impair the function of adjacent organs, leading to a cycle of worsening metabolic health.

Moreover, the concept of metabolic memory highlights how previous states of metabolic dysfunction, such as hyperglycemia or hyperlipidemia, can have long-lasting effects on organ function even after the resolution of these conditions. This phenomenon is characterized by chronic inflammatory responses and cellular alterations that can persist and lead to organ dysfunction over time [8]. For instance, the liver and cardiovascular system can be adversely affected by systemic metabolic dysfunction, which necessitates a collaborative approach between cardiology and hepatology to optimize treatment strategies [4].

Future directions in research must address the need for longitudinal studies that track the progression of metabolic diseases and their impact on organ function over time. Such studies are essential to understand the long-term consequences of metabolic dysfunction and to identify potential interventions that can mitigate these effects. By focusing on the systemic nature of metabolic diseases and their interactions with various organ systems, researchers can develop more comprehensive treatment strategies that target the underlying metabolic processes rather than solely addressing organ-specific sequelae [4].

In summary, metabolic diseases exert significant effects on organ function through inflammatory mechanisms, dysregulation of adipose tissue, and the persistence of metabolic memory. There is a pressing need for longitudinal studies to elucidate these relationships further and to develop effective interventions that address the multifaceted nature of metabolic disorders.

6.2 Exploring Genetic Factors ​

Metabolic diseases, including obesity, type 2 diabetes, and metabolic syndrome, significantly affect organ function through various mechanisms that involve both genetic and environmental factors. These diseases are characterized by complex interactions among multiple physiological systems, which can lead to dysfunction in key organs such as the heart, liver, and kidneys.

One primary mechanism by which metabolic diseases impact organ function is through alterations in metabolic pathways. For instance, the metabolic syndrome encompasses a range of risk factors, including hyperglycemia, dyslipidemia, and hypertension, which collectively elevate the risk for cardiovascular diseases. These risk factors result from dysregulated metabolic processes and contribute to the impairment of vascular endothelial and smooth muscle cell functions across various organ systems, including the heart and brain [6]. Furthermore, the development of insulin resistance and associated metabolic dysfunctions can directly affect the heart's structure and function, leading to cardiovascular complications [44].

Another significant factor is the role of epigenetic modifications in organ function. Environmental factors, such as maternal nutrition during pregnancy, can lead to epigenetic changes that affect organ development and function in offspring. For example, maternal metabolic disorders can influence cardiac development in offspring, potentially leading to structural and functional abnormalities that predispose them to cardiovascular issues later in life [44]. Similarly, dietary factors can induce epigenetic changes that alter gene expression involved in metabolic pathways, further complicating the relationship between diet, metabolism, and organ function [45].

Research has also indicated that circadian disruptions can exacerbate metabolic dysfunction, thereby impacting organ function. The circadian clock plays a crucial role in regulating metabolic processes, and disturbances in circadian rhythms have been linked to the pathogenesis of metabolic syndrome. Such disruptions can lead to impaired glucose and lipid metabolism, which in turn affect cardiovascular health and overall organ function [46].

Despite the progress in understanding the impact of metabolic diseases on organ function, significant research gaps remain. Future studies should focus on elucidating the precise molecular mechanisms underlying the interaction between genetic predispositions and environmental influences in metabolic diseases. This includes exploring the role of epigenetic modifications, circadian biology, and the influence of dietary components on organ health [47]. Additionally, the development of advanced human model systems, such as stem cell-derived organoids, may provide new insights into the pathophysiology of metabolic diseases and facilitate the identification of potential therapeutic targets [48].

In summary, metabolic diseases have profound effects on organ function through a combination of altered metabolic pathways, epigenetic modifications, and circadian disruptions. Addressing the gaps in current research will be crucial for developing effective interventions aimed at mitigating the impact of these diseases on organ health.

6.3 Integrating Multi-Omics Approaches ​

Metabolic diseases significantly impact organ function through a complex interplay of systemic effects that disrupt normal physiological processes. The rise in prevalence of conditions such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease has led to a greater understanding of how these diseases affect not only individual organs but also the interactions between multiple organ systems.

Research indicates that metabolic dysfunctions often result in alterations in organ-specific metabolism and can lead to the development of multi-organ complications. For instance, the interplay between the heart, liver, kidneys, and metabolic pathways is crucial in the pathophysiology of heart failure (HF). HF has been increasingly associated with comorbidities such as obesity and diabetes, emphasizing the importance of examining interorgan communication rather than treating each organ's dysfunction in isolation. Recent findings suggest that traditional epidemiological approaches that evaluate individual comorbidities may overlook shared mechanisms and complex bidirectional relationships among these conditions [49].

To address these intricate relationships, the integration of multi-omics approaches—combining genomics, proteomics, metabolomics, and other "-omics" technologies—has emerged as a promising strategy. This holistic view can elucidate the molecular and physiological events underlying metabolic diseases, allowing for a better understanding of the mechanisms linking genotype to disease phenotypes and therapeutic outcomes [50]. Multi-omics approaches provide insights into how various biological pathways are interconnected and how they contribute to the dysfunction of multiple organs. For example, metabolic profiling can reveal specific dysregulated pathways in conditions such as diabetes and obesity, which may impact cardiac and liver functions simultaneously [51].

Despite these advancements, significant research gaps remain. One of the critical challenges is the effective integration of diverse omics data, which requires robust bioinformatics tools and standardized protocols. The dynamic nature of metabolic processes further complicates the analysis, necessitating the development of innovative methodologies to manage and interpret high-dimensional data [52]. Additionally, there is a pressing need for more inclusive clinical trials that account for the complexity of multimorbidity and the interrelated nature of organ dysfunction [49].

Future research should focus on leveraging multi-organ microphysiological systems (MOMPS) to replicate human microphysiology and simulate organ interactions. These systems can help identify novel relationships between interorgan crosstalk, metabolism, and immunity, thereby enhancing our understanding of disease mechanisms and informing drug development [53]. Moreover, integrating findings from organoid models and stem cell research can provide further insights into the pathophysiology of metabolic diseases, offering potential avenues for personalized therapeutic strategies [48].

In summary, the impact of metabolic diseases on organ function is profound and multifaceted, highlighting the necessity for a comprehensive, integrative approach to research that encompasses the complexity of interorgan interactions. Addressing these future directions and research gaps will be crucial for advancing our understanding and management of metabolic diseases.

7 Conclusion ​

Metabolic diseases exert significant effects on organ function through complex mechanisms involving inflammation, oxidative stress, endothelial dysfunction, and altered metabolic pathways. The intricate interplay between these factors highlights the systemic nature of metabolic disorders, which not only compromise individual organ health but also contribute to the progression of multi-organ complications. Current research indicates that addressing these diseases requires a multidisciplinary approach, integrating insights from various fields such as cardiology, hepatology, and nephrology. Future research directions should focus on longitudinal studies to track the progression of metabolic diseases, explore genetic factors influencing organ function, and integrate multi-omics approaches to unravel the complex interactions between metabolic pathways and organ health. This comprehensive understanding is essential for developing targeted therapeutic strategies aimed at mitigating the impact of metabolic diseases on overall health and improving patient outcomes.

References ​

  • [1] Mohamed Badawy;Khaled M Elsayes;Meghan G Lubner;Mostafa A Shehata;Kathryn Fowler;Arwa Kaoud;Perry J Pickhardt. Metabolic syndrome: imaging features and clinical outcomes.. The British journal of radiology(IF=3.4). 2024. PMID:38308038. DOI: 10.1093/bjr/tqad044.
  • [2] A Masha;V Martina. Endothelial dysfunction in metabolic diseases: role of oxidation and possible therapeutic employment of N-acetylcysteine.. Current medicinal chemistry(IF=3.5). 2014. PMID:25005185. DOI: 10.2174/0929867321666140706132900.
  • [3] Kazuhiko Nishida;Kinya Otsu. Inflammation and metabolic cardiomyopathy.. Cardiovascular research(IF=13.3). 2017. PMID:28395010. DOI: 10.1093/cvr/cvx012.
  • [4] Paolo Raggi;Jovana Milic;Marcella Manicardi;Felice Cinque;Mark G Swain;Giada Sebastiani;Giovanni Guaraldi. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology.. Atherosclerosis(IF=5.7). 2024. PMID:38522165. DOI: 10.1016/j.atherosclerosis.2024.117523.
  • [5] Marilen Federico;Sergio De la Fuente;Julieta Palomeque;Shey-Shing Sheu. The role of mitochondria in metabolic disease: a special emphasis on heart dysfunction.. The Journal of physiology(IF=4.4). 2021. PMID:33932959. DOI: 10.1113/JP279376.
  • [6] Conor Willson;Makiko Watanabe;Atsumi Tsuji-Hosokawa;Ayako Makino. Pulmonary vascular dysfunction in metabolic syndrome.. The Journal of physiology(IF=4.4). 2019. PMID:30125956. DOI: 10.1113/JP275856.
  • [7] Mamatha Bhat;Shirine E Usmani;Amirhossein Azhie;Minna Woo. Metabolic Consequences of Solid Organ Transplantation.. Endocrine reviews(IF=22.0). 2021. PMID:33247713. DOI: 10.1210/endrev/bnaa030.
  • [8] Hao Dong;Yuezhang Sun;Lulingxiao Nie;Aimin Cui;Pengfei Zhao;Wai Keung Leung;Qi Wang. Metabolic memory: mechanisms and diseases.. Signal transduction and targeted therapy(IF=52.7). 2024. PMID:38413567. DOI: 10.1038/s41392-024-01755-x.
  • [9] Cornelius J Fernandez;Mohammed Alkhalifah;Hafsa Afsar;Joseph M Pappachan. Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink.. Pathogens (Basel, Switzerland)(IF=3.3). 2024. PMID:38251375. DOI: 10.3390/pathogens13010068.
  • [10] Giulio Marchesini;Rebecca Marzocchi. Metabolic syndrome and NASH.. Clinics in liver disease(IF=4.1). 2007. PMID:17544974. DOI: 10.1016/j.cld.2007.02.013.
  • [11] Csaba Matyas;György Haskó;Lucas Liaudet;Eszter Trojnar;Pal Pacher. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.. Nature reviews. Cardiology(IF=44.2). 2021. PMID:32999450. DOI: 10.1038/s41569-020-0433-5.
  • [12] Mengyao Yan;Yimin Cui;Qian Xiang. Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions.. Theranostics(IF=13.3). 2025. PMID:39897543. DOI: 10.7150/thno.106597.
  • [13] Bernard Fromenty;Michael Roden. Mitochondrial alterations in fatty liver diseases.. Journal of hepatology(IF=33.0). 2023. PMID:36209983. DOI: 10.1016/j.jhep.2022.09.020.
  • [14] Raja Ganesan;Durairaj Thirumurugan;Saranya Vinayagam;Dong Joon Kim;Ki Tae Suk;Mahalaxmi Iyer;Mukesh Kumar Yadav;Dibbanti HariKrishnaReddy;Jyoti Parkash;Arvinder Wander;Balachandar Vellingiri. A critical review of microbiome-derived metabolic functions and translational research in liver diseases.. Frontiers in cellular and infection microbiology(IF=4.8). 2025. PMID:40066068. DOI: 10.3389/fcimb.2025.1488874.
  • [15] Lixiao Hang;Ying Zhang;Zheng Zhang;Haiqiang Jiang;Lin Xia. Metabolism Serves as a Bridge Between Cardiomyocytes and Immune Cells in Cardiovascular Diseases.. Cardiovascular drugs and therapy(IF=3.1). 2025. PMID:38236378. DOI: 10.1007/s10557-024-07545-5.
  • [16] Michael Gao;Toren Finkel. Metabolic Regulation of Cardiovascular Aging.. Current cardiology reports(IF=3.3). 2025. PMID:40815457. DOI: 10.1007/s11886-025-02279-8.
  • [17] Adina V Lința;Bogdan M Lolescu;Cosmin A Ilie;Mihaela Vlad;Alexandru Blidișel;Adrian Sturza;Claudia Borza;Danina M Muntean;Octavian M Crețu. Liver and Pancreatic Toxicity of Endocrine-Disruptive Chemicals: Focus on Mitochondrial Dysfunction and Oxidative Stress.. International journal of molecular sciences(IF=4.9). 2024. PMID:39000526. DOI: 10.3390/ijms25137420.
  • [18] Timon E Adolph;Lisa Mayr;Felix Grabherr;Julian Schwärzler;Herbert Tilg. Pancreas-Microbiota Cross Talk in Health and Disease.. Annual review of nutrition(IF=13.4). 2019. PMID:31433743. DOI: 10.1146/annurev-nutr-082018-124306.
  • [19] Joshua Reed;Stephen C Bain;Venkateswarlu Kanamarlapudi. The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets.. Diabetes, metabolic syndrome and obesity : targets and therapy(IF=3.0). 2024. PMID:38894706. DOI: 10.2147/DMSO.S415934.
  • [20] Maxim S Petrov. Metabolic Trifecta After Pancreatitis: Exocrine Pancreatic Dysfunction, Altered Gut Microbiota, and New-Onset Diabetes.. Clinical and translational gastroenterology(IF=3.0). 2019. PMID:31609744. DOI: 10.14309/ctg.0000000000000086.
  • [21] Julia Phieler;Ruben Garcia-Martin;John D Lambris;Triantafyllos Chavakis. The role of the complement system in metabolic organs and metabolic diseases.. Seminars in immunology(IF=7.8). 2013. PMID:23684628. DOI: .
  • [22] Rocio Guadalupe Hernández-Ruiz;Xochitl Citalli Olivares-Ochoa;Yahatziri Salinas-Varela;David Guajardo-Espinoza;Luis Gustavo Roldán-Flores;Edgar Alfonso Rivera-Leon;Andres López-Quintero. Phenolic Compounds and Anthocyanins in Legumes and Their Impact on Inflammation, Oxidative Stress, and Metabolism: Comprehensive Review.. Molecules (Basel, Switzerland)(IF=4.6). 2025. PMID:39795230. DOI: 10.3390/molecules30010174.
  • [23] Lanlan Li;Zhiliang Guo;Yi Zhao;Chuanjie Liang;Wenxiang Zheng;Wenxiu Tian;Yalin Chen;Yi Cheng;Fengwen Zhu;Xinxin Xiang. The impact of oxidative stress on abnormal lipid metabolism-mediated disease development.. Archives of biochemistry and biophysics(IF=3.0). 2025. PMID:39961502. DOI: 10.1016/j.abb.2025.110348.
  • [24] Triantafyllos Chavakis;Vasileia Ismini Alexaki;Anthony W Ferrante. Macrophage function in adipose tissue homeostasis and metabolic inflammation.. Nature immunology(IF=27.6). 2023. PMID:37012544. DOI: 10.1038/s41590-023-01479-0.
  • [25] León Ferder;Felipe Inserra;Manuel Martínez-Maldonado. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress.. Current hypertension reports(IF=5.1). 2006. PMID:17147916. DOI: 10.1007/s11906-006-0050-7.
  • [26] Fulvio Chiacchiera;Andrea Piunti;Diego Pasini. Epigenetic methylations and their connections with metabolism.. Cellular and molecular life sciences : CMLS(IF=6.2). 2013. PMID:23456257. DOI: 10.1007/s00018-013-1293-5.
  • [27] Caterina Constantinou;Eleni A Karavia;Eva Xepapadaki;Peristera-Ioanna Petropoulou;Eugenia Papakosta;Marilena Karavyraki;Evangelia Zvintzou;Vassilis Theodoropoulos;Serafoula Filou;Aikaterini Hatziri;Christina Kalogeropoulou;George Panayiotakopoulos;Kyriakos E Kypreos. Advances in high-density lipoprotein physiology: surprises, overturns, and promises.. American journal of physiology. Endocrinology and metabolism(IF=3.1). 2016. PMID:26530157. DOI: 10.1152/ajpendo.00429.2015.
  • [28] Kyung-Sun Heo;Lan Phuong Phan;Nhi Thi Thao Le;Yujin Jin. Mechanistic insights and emerging therapeutic strategies targeting endothelial dysfunction in cardiovascular diseases.. Archives of pharmacal research(IF=7.5). 2025. PMID:40301174. DOI: 10.1007/s12272-025-01542-4.
  • [29] Jeong-a Kim;Monica Montagnani;Kwang Kon Koh;Michael J Quon. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.. Circulation(IF=38.6). 2006. PMID:16618833. DOI: 10.1161/CIRCULATIONAHA.105.563213.
  • [30] Seung Hwan Han;Michael J Quon;Kwang Kon Koh. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction.. Current opinion in lipidology(IF=4.6). 2007. PMID:17218834. DOI: 10.1097/MOL.0b013e328012b627.
  • [31] Ashton Faulkner. Trans-endothelial trafficking of metabolic substrates and its importance in cardio-metabolic disease.. Biochemical Society transactions(IF=4.3). 2021. PMID:33616631. DOI: 10.1042/BST20200991.
  • [32] L Hou;M Zhang;L Liu;Q Zhong;M Xie;G Zhao. Therapeutic applications of nanomedicine in metabolic diseases by targeting the endothelium.. QJM : monthly journal of the Association of Physicians(IF=6.4). 2023. PMID:36063067. DOI: 10.1093/qjmed/hcac210.
  • [33] Alessia Fornoni;Leopoldo Raij. Metabolic syndrome and endothelial dysfunction.. Current hypertension reports(IF=5.1). 2005. PMID:15748531. DOI: 10.1007/s11906-005-0080-6.
  • [34] Alessandra Pasut;Eleonora Lama;Amaryllis H Van Craenenbroeck;Jeffrey Kroon;Peter Carmeliet. Endothelial cell metabolism in cardiovascular physiology and disease.. Nature reviews. Cardiology(IF=44.2). 2025. PMID:40346347. DOI: 10.1038/s41569-025-01162-x.
  • [35] Riccardo Dalle Grave;Simona Calugi;Elena Centis;Rebecca Marzocchi;Marwan El Ghoch;Giulio Marchesini. Lifestyle modification in the management of the metabolic syndrome: achievements and challenges.. Diabetes, metabolic syndrome and obesity : targets and therapy(IF=3.0). 2010. PMID:21437107. DOI: 10.2147/DMSOTT.S13860.
  • [36] Luca Montesi;Simona Moscatiello;Marcella Malavolti;Rebecca Marzocchi;Giulio Marchesini. Physical activity for the prevention and treatment of metabolic disorders.. Internal and emergency medicine(IF=3.8). 2013. PMID:23657989. DOI: 10.1007/s11739-013-0953-7.
  • [37] Giovanni Martemucci;Mohamad Khalil;Alessio Di Luca;Hala Abdallah;Angela Gabriella D'Alessandro. Comprehensive Strategies for Metabolic Syndrome: How Nutrition, Dietary Polyphenols, Physical Activity, and Lifestyle Modifications Address Diabesity, Cardiovascular Diseases, and Neurodegenerative Conditions.. Metabolites(IF=3.7). 2024. PMID:38921462. DOI: 10.3390/metabo14060327.
  • [38] Ibrahim AlZaim;Ali H Eid;Khaled S Abd-Elrahman;Ahmed F El-Yazbi. Adipose tissue mitochondrial dysfunction and cardiometabolic diseases: On the search for novel molecular targets.. Biochemical pharmacology(IF=5.6). 2022. PMID:36347272. DOI: 10.1016/j.bcp.2022.115337.
  • [39] Sanjun Shi;Na Kong;Chan Feng;Aram Shajii;Claire Bejgrowicz;Wei Tao;Omid C Farokhzad. Drug Delivery Strategies for the Treatment of Metabolic Diseases.. Advanced healthcare materials(IF=9.6). 2019. PMID:30957991. DOI: 10.1002/adhm.201801655.
  • [40] Asen Georgiev;Cesare Granata;Michael Roden. The role of mitochondria in the pathophysiology and treatment of common metabolic diseases in humans.. American journal of physiology. Cell physiology(IF=4.7). 2022. PMID:35508191. DOI: 10.1152/ajpcell.00035.2022.
  • [41] Yifei Chen;Fuji Yang;Ying Chu;Zhihua Yun;Yongmin Yan;Jianhua Jin. Mitochondrial transplantation: opportunities and challenges in the treatment of obesity, diabetes, and nonalcoholic fatty liver disease.. Journal of translational medicine(IF=7.5). 2022. PMID:36273156. DOI: 10.1186/s12967-022-03693-0.
  • [42] Alessandra Castegna;Rosanna Gissi;Alessio Menga;Monica Montopoli;Maria Favia;Antonella Viola;Marcella Canton. Pharmacological targets of metabolism in disease: Opportunities from macrophages.. Pharmacology & therapeutics(IF=12.5). 2020. PMID:32151665. DOI: 10.1016/j.pharmthera.2020.107521.
  • [43] Kexin Zhang;Jingwen Zhang;Chengxia Kan;Hongzhan Tian;Yanhui Ma;Na Huang;Fang Han;Ningning Hou;Xiaodong Sun. Role of dysfunctional peri-organ adipose tissue in metabolic disease.. Biochimie(IF=3.0). 2023. PMID:37019205. DOI: 10.1016/j.biochi.2023.03.015.
  • [44] Zhuoran Ren;Sisi Luo;Jiajun Cui;Yunhui Tang;Hefeng Huang;Guolian Ding. Research Progress of Maternal Metabolism on Cardiac Development and Function in Offspring.. Nutrients(IF=5.0). 2023. PMID:37571325. DOI: 10.3390/nu15153388.
  • [45] Jae-Ho Park;Soon-Hee Kim;Myeong Soo Lee;Myung-Sunny Kim. Epigenetic modification by dietary factors: Implications in metabolic syndrome.. Molecular aspects of medicine(IF=10.3). 2017. PMID:28216432. DOI: 10.1016/j.mam.2017.01.008.
  • [46] Eleonore Maury;Kathryn Moynihan Ramsey;Joseph Bass. Circadian rhythms and metabolic syndrome: from experimental genetics to human disease.. Circulation research(IF=16.2). 2010. PMID:20167942. DOI: 10.1161/CIRCRESAHA.109.208355.
  • [47] Rachel Stegemann;David A Buchner. Transgenerational inheritance of metabolic disease.. Seminars in cell & developmental biology(IF=6.0). 2015. PMID:25937492. DOI: 10.1016/j.semcdb.2015.04.007.
  • [48] Wenxiang Hu;Mitchell A Lazar. Modelling metabolic diseases and drug response using stem cells and organoids.. Nature reviews. Endocrinology(IF=40.0). 2022. PMID:36071283. DOI: 10.1038/s41574-022-00733-z.
  • [49] Chang Jie Mick Lee;Leah B Kosyakovsky;Muhammad Shahzeb Khan;Feng Wu;Guo Chen;Joseph A Hill;Jennifer E Ho;Roger S-Y Foo;Faiez Zannad. Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos.. Circulation research(IF=16.2). 2025. PMID:40403106. DOI: 10.1161/CIRCRESAHA.125.325602.
  • [50] Omar Ramos-Lopez;J Alfredo Martinez;Fermin I Milagro. Holistic Integration of Omics Tools for Precision Nutrition in Health and Disease.. Nutrients(IF=5.0). 2022. PMID:36235725. DOI: 10.3390/nu14194074.
  • [51] Mireia Valles-Colomer;Cristina Menni;Sarah E Berry;Ana M Valdes;Tim D Spector;Nicola Segata. Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective.. Nature medicine(IF=50.0). 2023. PMID:36932240. DOI: 10.1038/s41591-023-02260-4.
  • [52] Yan Zhang;Biyan Huang;Jiao Jin;Yao Xiao;Huimin Ying. Recent advances in the application of ionomics in metabolic diseases.. Frontiers in nutrition(IF=5.1). 2022. PMID:36726817. DOI: 10.3389/fnut.2022.1111933.
  • [53] Joeng Ju Kim;Mihyeon Bae;Dong-Woo Cho. Multi-Organ Microphysiological Systems Targeting Specific Organs for Recapitulating Disease Phenotypes via Organ Crosstalk.. Small science(IF=8.3). 2024. PMID:40213438. DOI: 10.1002/smsc.202400314.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Metabolic Diseases · Organ Function · Inflammation · Oxidative Stress · Therapeutic Strategies

© 2025 MaltSci